HANSEN MEDICAL INC
SymbolHNSN

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

The Shuman Law Firm Announces the Filing of a Class Action Lawsuit Against Hansen Medical, Inc.

2009-10-26 18:01 ET - News Release

BOULDER, Colo., Oct. 26, 2009 (GLOBE NEWSWIRE) -- Advertising Material -- The Shuman Law Firm today announced that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of a class (the "Class") consisting of all persons or entities who purchased the securities of Hansen Medical, Inc. ("Hansen" or the "Company") (Nasdaq:HNSN) between May 1, 2008 and October 18, 2009, inclusive (the "Class Period").

If you wish to discuss this action or have any questions concerning this notice or your rights and interests with respect to this matter, please contact Kip B. Shuman or Rusty E. Glenn toll free at (866) 974-8626 or email Mr. Shuman at kip@shumanlawfirm.com or Mr. Glenn at rusty@shumanlawfirm.com.

The Complaint charges the Company and certain of its executive officers with violations of federal securities laws. Hansen develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Complaint alleges that defendants knew or recklessly disregarded that their public statements concerning Hansen's business, operations and prospects were materially false and misleading. Specifically, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company improperly recognized revenue; (2) as a result, the Company's revenue and financial results were overstated during the Class Period; (3) the Company's financial results were not prepared in accordance with Generally Accepted Accounting Principles; (4) the Company lacked adequate internal and financial controls; and (5), as a result of the above, the Company's financial statements were materially false and misleading at all relevant times.

The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try, click here for a free 30 day trial subscription.